Literature DB >> 32382776

Signals of Th2 immune response from COVID-19 patients requiring intensive care.

Luca Roncati1, Vincenzo Nasillo2, Beatrice Lusenti2, Giovanni Riva2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32382776      PMCID: PMC7205481          DOI: 10.1007/s00277-020-04066-7

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


× No keyword cloud information.
Dear Editor, Naїve T-helper cells (Th0) can respond to novel pathogens that the immune system has never encountered before, as is the specific case of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the positive-sense single-stranded RNA virus responsible for the ongoing pandemic named coronavirus disease 2019 (COVID-19). Depending on the infectious agent, Th0 polarize the immune response into T-helper type 1 (Th1), the default response in immunocompetent subjects to intracellular or phagocytosable pathogens (e.g. viruses, bacteria, protozoa, fungi) and mediated by macrophages and T-cytotoxic (Tc) cells (cell-mediated immunity), or into T-helper type 2 (Th2), classically directed against extracellular non-phagocytosable pathogens, for instance helminths, and whose main effectors are eosinophils, basophils and mastocytes, as well as B cells (humoral immunity) [1]. Eosinophils play a direct role in fighting RNA viruses, as demonstrated by the presence of RNases inside their granules [1]; however, they have been negatively associated with the pathophysiology of the respiratory virus infections, since they trigger bronchoconstriction and dyspnea, besides virus-induced exacerbations of allergic airways diseases, by releasing a large amount of cationic proteins and cytokines, among which interleukin-6 (IL-6), a key mediator also for the development of the “cytokine storm” in COVID-19 fatal cases [2, 3]. At some extent, the smooth muscle cells in the tunica media of blood vessels can produce IL-6, too [4]. It belongs to Th2 cytokines class together with IL-4, IL-5, IL-9, IL-10, IL-13 and IL-25; contrariwise, IL-2, IL-12, interferon-γ and tumor necrosis factor-α are the main Th1 cytokines, able to stimulate the inducible form of the nitric oxide (NO) synthase to produce NO free radicals endowed with virucidal activity [1]. To minimize the contagion risk in healthcare personnel, we have prepared and examined a limited number of 15 peripheral blood smears from a wider series of hospitalized COVID-19 patients, just admitted to intensive care and monitored through blood tests; in all the cases, we have found cytological signals of Th2 immune response, represented by eosinophilia plus basophilia, degranulated eosinophils, Türk cells or plasma cells, together with rouleaux and Tc lymphopenia (Fig. 1). On the basis of our findings, for reasons still unclear, maybe related to the viral load, Th1 and Tc breakdown, antigenic cross-reactivity or the type of antigen-presenting cell stimulating Th0, the immune system mounts a Th2 response against SARS-CoV-2 in patients requiring intensive care, rather than a Th1 response, which would keep the infection under control by means of macrophages and Tc cells. This event is more likely in patients affected by cancer, immunodeficiency, autoimmune disorders, congestive heart failure, chronic obstructive pulmonary disease and hepatic cirrhosis, or in those who have suffered major surgery and traumatic injury, or who are on glucocorticoid therapy and total parenteral nutrition, all known conditions suppressive to Th1 immunity [1]. The mounting of a Th2 immune response allows to explain well the concurrent gastrointestinal symptoms present up to 30% of COVID-19 patients and significantly associated with dyspnea [5]; in fact, hyperperistalsis and gastric fluid acidification are also two notorious default mechanisms of defense to expel parasites governed by Th2 cytokines [1].
Fig. 1

Cytological signals of Th2 immune response on peripheral blood smears from COVID-19 patients requiring intensive care: a on the right side of the panel, three eosinophils in a row accompanied by a basophile in the upper left corner (× 40 objective); b an eosinophil in the degranulation phase (× 100 objective); c a bilobed degranulated eosinophil in the center of the panel (× 100 objective); d an immature plasma cell (Türk cell) in the midst of prominent rouleaux (× 100 objective) (May-Grünwald stain)

Cytological signals of Th2 immune response on peripheral blood smears from COVID-19 patients requiring intensive care: a on the right side of the panel, three eosinophils in a row accompanied by a basophile in the upper left corner (× 40 objective); b an eosinophil in the degranulation phase (× 100 objective); c a bilobed degranulated eosinophil in the center of the panel (× 100 objective); d an immature plasma cell (Türk cell) in the midst of prominent rouleaux (× 100 objective) (May-Grünwald stain)
  4 in total

1.  Aging enhances the basal production of IL-6 and CCL2 in vascular smooth muscle cells.

Authors:  Yang Song; Hua Shen; Dominik Schenten; Peiying Shan; Patty J Lee; Daniel R Goldstein
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-10-27       Impact factor: 8.311

Review 2.  Type 1/Type 2 immunity in infectious diseases.

Authors:  B Spellberg; J E Edwards
Journal:  Clin Infect Dis       Date:  2000-12-15       Impact factor: 9.079

3.  Eosinophils and their interactions with respiratory virus pathogens.

Authors:  Helene F Rosenberg; Kimberly D Dyer; Joseph B Domachowske
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829

4.  Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality.

Authors:  Chi Zhang; Zhao Wu; Jia-Wen Li; Hong Zhao; Gui-Qiang Wang
Journal:  Int J Antimicrob Agents       Date:  2020-03-29       Impact factor: 5.283

  4 in total
  41 in total

1.  The Novel Coronavirus and Inflammation.

Authors:  J A George; E S Mayne
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  Efficacy and safety of corticosteroid regimens for the treatment of hospitalized COVID-19 patients: a meta-analysis.

Authors:  Fangwen Zhou; Jiawen Deng; Kiyan Heybati; Qi Kang Zuo; Saif Ali; Wenteng Hou; Chi Yi Wong; Harikrishnaa Ba Ramaraju; Oswin Chang; Thanansayan Dhivagaran; Zachary Silver
Journal:  Future Virol       Date:  2022-06-03       Impact factor: 3.015

3.  Cytokine release syndrome in COVID-19: Innate immune, vascular, and platelet pathogenic factors differ in severity of disease and sex.

Authors:  Aaron C Petrey; Fares Qeadan; Elizabeth A Middleton; Irina V Pinchuk; Robert A Campbell; Ellen J Beswick
Journal:  J Leukoc Biol       Date:  2020-09-15       Impact factor: 4.962

4.  Investigating Cellular Trajectories in the Severity of COVID-19 and Their Transcriptional Programs Using Machine Learning Approaches.

Authors:  Hyun-Hwan Jeong; Johnathan Jia; Yulin Dai; Lukas M Simon; Zhongming Zhao
Journal:  Genes (Basel)       Date:  2021-04-24       Impact factor: 4.096

5.  Cytomegalovirus haemorrhagic colitis complicating COVID-19 in an immunocompetent critically ill patient: A case report.

Authors:  Sophie Leemans; Evelyne Maillart; Héloïse Van Noten; Lucas Oliveira Dos Santos; Laura Maria Leahu; Prochore Kamgang; Andrea Gallerani; Philippe Clevenbergh
Journal:  Clin Case Rep       Date:  2020-12-05

6.  COVID-19, Severe Asthma and Omalizumab Therapy: A Case-Based Inquiry into Associations, Management, and the Possibility of a Better Outcome.

Authors:  Sadi Can Sönmez; Zeynep Büşra Kısakürek; Ayse Bilge Ozturk; Süda Tekin
Journal:  Turk Thorac J       Date:  2021-11

7.  The Immunopathobiology of SARS-CoV-2 Infection.

Authors:  Milankumar Patel; Farah Shahjin; Jacob D Cohen; Mahmudul Hasan; Jatin Machhi; Heerak Chugh; Snigdha Singh; Srijanee Das; Tanmay A Kulkarni; Jonathan Herskovitz; Douglas D Meigs; Ramesh Chandra; Kenneth S Hettie; R Lee Mosley; Bhavesh D Kevadiya; Howard E Gendelman
Journal:  FEMS Microbiol Rev       Date:  2021-11-23       Impact factor: 16.408

Review 8.  Narrative review of the relationship between COVID-19 and PJP: does it represent coinfection or colonization?

Authors:  Woon H Chong; Biplab K Saha; Amit Chopra
Journal:  Infection       Date:  2021-05-31       Impact factor: 3.553

9.  Lymphocyte subset alterations with disease severity, imaging manifestation, and delayed hospitalization in COVID-19 patients.

Authors:  Daxian Wu; Xiaoping Wu; Jiansheng Huang; Qunfang Rao; Qi Zhang; Wenfeng Zhang
Journal:  BMC Infect Dis       Date:  2021-07-01       Impact factor: 3.090

10.  Subacute effusive-constrictive pericarditis in a patient with COVID-19.

Authors:  Rodica Diaconu; Lucian Popescu; Anda Voicu; Ionut Donoiu
Journal:  BMJ Case Rep       Date:  2021-06-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.